← All trials
NCT07069725
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 26, 2025
- Primary completion
- Mar 31, 2026
- Completion date
- Mar 31, 2026
- First posted
- Jul 17, 2025
- Last posted
- Nov 28, 2025
- Enrollment
- 12
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
- Clinical Trial Consultants ABCollaborator
- Karolinska InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.